Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)


The aim of this study is to test the hypothesis that canakinumab treatments will prevent recurrent cardiovascular events. This study will include blood draws, physical exams, vital signs, urine collection, EKGs and study drug dispensing. All study related testing will be completed at no cost to the patient. Compensation may occur for qualified patients.

This Study Is Closed To Enrollment.
 

©2018 Heart Consultants P.C. All Rights Reserved